The Future of Psychedelic Medicine & Ketamine Therapy with Dylan Beynon the CEO of Mindbloom | Maximus Podcast

This episode of the Maximus Podcast is Part 2 of the interview with Dylan Beynon the CEO of Mindbloom. Dylan talks about his company, why he started Mindbloom and what they provide for their patients. Dylan also talks about why they focus on Ketamine assisted psychotherapy and the neurological affects Ketamine has on the brain. Also, Dr. Cam and Dylan discuss the future of telemedicine and give some insights on why psychedelics need to be more accessible to those suffering from different psychological disorders such as depression, PTSD, OCD and other anxiety disorders.  Get more information about Mindbloom: https://www.mindbloom.com/ Maximize your testosterone today: https://tinyurl.com/MTYouTubeOrg